For 1 suppository:
Active ingredient - sodium aminodihydrophthalazindione (Galavit®) 100 mg;
excipients - vitepsol W-35 (fatty acid glycerides)
- 575 mg, vitepsol H-15 (fatty acid glycerides) - 575 mg.
Pharmacotherapeutic group
immunomodulatory and anti-inflammatory agent
The mechanism of action of the drug is associated with its ability to regulate
functional and metabolic activity of innate and adaptive immune cells (monocytes, macrophages, neutrophils, natural killer cells, etc.). Galavit normalizes the phagocytic activity of monocytes/macrophages, the bactericidal activity of neutrophils and the cytotoxic activity of NK cells.
At the same time, by restoring the reduced activity of innate and adaptive immune cells, the drug increases the body’s resistance to infectious diseases.
In addition, Galavit normalizes antibody formation and increases the functional activity (affinity) of antibodies.
In inflammatory diseases, the drug reversibly inhibits for 6-8 hours the excessive synthesis of tumor necrosis factor-α, interleukin-1, interleukin-6 and other pro-inflammatory cytokines by hyperactivated macrophages, the level of which determines the degree of inflammatory reactions, their
cyclicality, as well as the severity of intoxication of the body. Galavit reduces the production of reactive oxygen species by hyperactivated macrophages, thereby
thereby reducing the level of oxidative stress and protecting tissues and organs from the destructive effects of radicals.
Normalization of excessively increased functional activity of phagocytic cells leads to the restoration of their antigen-presenting and regulatory functions, and a decrease in the level of autoaggression.
The drug has no allergenic, mutagenic, embryotoxic, teratogenic or carcinogenic effects.
It is excreted from the body mainly through the kidneys. After rectal use
The half-life is 40-60 minutes. The main pharmacological effects are observed within 72 hours. Aminodihydrophthalazindione sodium in suppositories when administered rectally has high bioavailability, and therefore both local and pronounced systemic effects are achieved.
Indications
As an immunomodulatory and anti-inflammatory agent in the complex therapy of immunodeficiency conditions in adults and adolescents over 12 years of age:
- infectious and inflammatory urogenital diseases (urethritis of chlamydial and trichomonas etiology; chlamydial prostatitis, acute and chronic salpingoophoritis, endometritis);
- purulent-inflammatory diseases of the pelvic organs;
- chronic recurrent diseases caused by the herpes virus;
- diseases caused by the papilloma virus;
- postoperative rehabilitation of patients with uterine fibroids;
- complications of the postoperative period in women of reproductive age;
- postoperative purulent-septic complications and their prevention (including in cancer patients);
- chronic recurrent furunculosis, erysipelas;
- nonspecific prevention and treatment of influenza and acute respiratory infections;
- inflammatory diseases of the mucous membrane of the mouth and throat, periodontal diseases;
- viral hepatitis;
- infectious intestinal diseases accompanied by intoxication and/or diarrhea
- peptic ulcer of the stomach and duodenum
- asthenic conditions, neurotic and somatoform disorders, decreased physical performance (including among athletes); mental,
behavioral and post-withdrawal disorders in alcohol and drug addiction
Contraindications
Hypersensitivity to Galavit and other components of the drug, pregnancy and breastfeeding, children under 12 years of age.
Use during pregnancy and breastfeeding:
The use of the drug is contraindicated during pregnancy and breastfeeding.
Directions for use and doses
Rectally. The suppository is released from the contour packaging and then inserted into the rectum. It is recommended to empty the intestines first.
The dose and duration of use of the drug depends on the nature, severity and duration of the disease.
- For urogenital diseases
- urethritis of chlamydial and trichomonas etiology, chlamydial prostatitis: 1 day, 1 suppository twice, then one every other day. A course of 10-15 suppositories (depending on the severity of the pathological process).
- For salpingoophoritis, endometritis in the acute period: 2 days, 2 suppositories once a day, then one at an interval of 72 hours. In the chronic period: 5 days, 1 suppository once a day, then one every 72 hours. Course - 20 suppositories.
- For acute and chronic
purulent diseases of the pelvic organs - in the acute period: 1 day, 2 suppositories once, 3 days, one suppository daily, then one every other day for 5 days. Course - 10 suppositories. In the chronic period: 5 days, 1 suppository once a day, then one every 72 hours. Course - 20 suppositories.
- For chronic recurrent diseases caused by a virus
